BidaskClub lowered shares of Shire (NASDAQ:SHPG) from a hold rating to a sell rating in a research report sent to investors on Thursday, June 21st.
Several other brokerages have also recently commented on SHPG. Kepler Capital Markets reaffirmed a buy rating on shares of Shire in a report on Friday, May 11th. BTIG Research reaffirmed a buy rating and set a $195.00 target price on shares of Shire in a report on Sunday, April 29th. Royal Bank of Canada reaffirmed a buy rating on shares of Shire in a report on Tuesday, May 8th. B. Riley raised their target price on shares of Shire to $200.00 and gave the stock a buy rating in a report on Thursday, April 19th. Finally, Zacks Investment Research upgraded shares of Shire from a sell rating to a hold rating in a research report on Monday, April 23rd. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have given a buy rating to the company. Shire currently has a consensus rating of Hold and an average target price of $201.64.
Shares of Shire opened at $168.80 on Thursday, according to MarketBeat. Shire has a 12 month low of $123.73 and a 12 month high of $177.51. The company has a market cap of $51.19 billion, a PE ratio of 10.95, a price-to-earnings-growth ratio of 1.40 and a beta of 1.29. The company has a current ratio of 1.14, a quick ratio of 0.66 and a debt-to-equity ratio of 0.45.
Shire (NASDAQ:SHPG) last announced its earnings results on Thursday, April 26th. The biopharmaceutical company reported $3.86 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.58 by $0.28. Shire had a net margin of 28.96% and a return on equity of 13.60%. The company had revenue of $3.77 billion for the quarter. During the same period in the prior year, the business posted $3.63 earnings per share. The firm’s revenue for the quarter was up 5.4% compared to the same quarter last year. equities analysts predict that Shire will post 15.27 EPS for the current year.
A number of institutional investors have recently modified their holdings of the business. Avalon Advisors LLC boosted its position in Shire by 21.5% in the first quarter. Avalon Advisors LLC now owns 7,116 shares of the biopharmaceutical company’s stock valued at $1,063,000 after buying an additional 1,261 shares in the last quarter. Mount Yale Investment Advisors LLC acquired a new stake in Shire in the first quarter valued at approximately $706,000. Suntrust Banks Inc. boosted its position in Shire by 42.5% in the first quarter. Suntrust Banks Inc. now owns 4,478 shares of the biopharmaceutical company’s stock valued at $667,000 after buying an additional 1,335 shares in the last quarter. Atlantic Trust Group LLC boosted its position in Shire by 35.8% in the first quarter. Atlantic Trust Group LLC now owns 35,353 shares of the biopharmaceutical company’s stock valued at $5,282,000 after buying an additional 9,328 shares in the last quarter. Finally, Israel Discount Bank of New York boosted its position in Shire by 11.9% in the first quarter. Israel Discount Bank of New York now owns 4,734 shares of the biopharmaceutical company’s stock valued at $708,000 after buying an additional 504 shares in the last quarter. Hedge funds and other institutional investors own 17.92% of the company’s stock.
Shire Company Profile
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.